3.65
price up icon13.00%   0.42
 
loading
Immunitybio Inc stock is traded at $3.65, with a volume of 3.07M. It is up +13.00% in the last 24 hours and up +0.83% over the past month. ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
See More
Previous Close:
$3.23
Open:
$3.2
24h Volume:
3.07M
Relative Volume:
1.13
Market Cap:
$2.54B
Revenue:
$302.00K
Net Income/Loss:
$-600.96M
P/E Ratio:
-3.2018
EPS:
-1.14
Net Cash Flow:
$-412.85M
1W Performance:
+6.41%
1M Performance:
+0.83%
6M Performance:
-39.77%
1Y Performance:
+168.38%
1-Day Range:
Value
$3.1939
$3.72
1-Week Range:
Value
$3.1939
$3.72
52-Week Range:
Value
$1.25
$10.53

Immunitybio Inc Stock (IBRX) Company Profile

Name
Name
Immunitybio Inc
Name
Phone
(844) 696-5235
Name
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Name
Employee
622
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
IBRX's Discussions on Twitter

Immunitybio Inc Stock (IBRX) Upgrades & Downgrades

Date Action Analyst Rating Change
May-12-23 Downgrade Piper Sandler Overweight → Neutral
Aug-03-22 Initiated Jefferies Buy

Immunitybio Inc Stock (IBRX) Latest News

pulisher
Oct 11, 2024

ImmunityBio (NASDAQ:IBRX) Trading Up 6.2%Time to Buy? - MarketBeat

Oct 11, 2024
pulisher
Oct 11, 2024

IMMUNITYBIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ImmunityBio, Inc.IBRX - PR Newswire

Oct 11, 2024
pulisher
Oct 09, 2024

ImmunityBio (NASDAQ:IBRX) Trading Down 4.5%Time to Sell? - MarketBeat

Oct 09, 2024
pulisher
Oct 07, 2024

ImmunityBio Stock: Moving The Needle (NASDAQ:IBRX) - Seeking Alpha

Oct 07, 2024
pulisher
Oct 02, 2024

More Layoffs From ImmunityBio, Bringing California’s Fall Cuts to 31 - BioSpace

Oct 02, 2024
pulisher
Sep 26, 2024

Profund Advisors LLC Sells 121,163 Shares of ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World

Sep 26, 2024
pulisher
Sep 25, 2024

Blair William & Co. IL Sells 106,742 Shares of ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World

Sep 25, 2024
pulisher
Sep 22, 2024

Rhumbline Advisers Has $1.34 Million Stake in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World

Sep 22, 2024
pulisher
Sep 21, 2024

ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt (NASDAQ:IBRX) - Seeking Alpha

Sep 21, 2024
pulisher
Sep 17, 2024

ImmunityBio (NASDAQ:IBRX) Shares Down 3.2% - MarketBeat

Sep 17, 2024
pulisher
Sep 15, 2024

Bank of New York Mellon Corp Acquires 170,742 Shares of ImmunityBio, Inc. (NASDAQ:IBRX) - MarketBeat

Sep 15, 2024
pulisher
Sep 12, 2024

Immunitybio Inc. (IBRX): Fast-Growing Penny Stock To Consider - Insider Monkey

Sep 12, 2024
pulisher
Sep 12, 2024

Immunitybio Inc. (IBRX): Fast-Growing Penny Stock To Consider - Yahoo Finance

Sep 12, 2024
pulisher
Sep 11, 2024

18,704 Shares in ImmunityBio, Inc. (NASDAQ:IBRX) Purchased by CIBC Asset Management Inc - Defense World

Sep 11, 2024
pulisher
Sep 10, 2024

ImmunityBio reports extended survival in NSCLC therapy trial By Investing.com - Investing.com Australia

Sep 10, 2024
pulisher
Sep 09, 2024

ImmunityBio reports extended survival in NSCLC therapy trial - Investing.com India

Sep 09, 2024
pulisher
Sep 09, 2024

ImmunityBio (NASDAQ:IBRX) Trading 6.8% Higher - MarketBeat

Sep 09, 2024
pulisher
Sep 09, 2024

ImmunityBio reports extended survival in NSCLC therapy trial - Investing.com

Sep 09, 2024
pulisher
Sep 09, 2024

ImmunityBio reports extended survival in NSCLC therapy trial By Investing.com - Investing.com Canada

Sep 09, 2024
pulisher
Sep 09, 2024

ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer - Business Wire

Sep 09, 2024
pulisher
Sep 04, 2024

Analysts Predict Strong Growth for Cancer Vaccine Market: Key Biotech Stocks to Consider - Baystreet.ca

Sep 04, 2024
pulisher
Sep 03, 2024

ImmunityBio lays off workers in Louisville - BizWest

Sep 03, 2024
pulisher
Sep 03, 2024

Amid Major Threats, Merck Stock Is A Sell (NYSE:MRK) - Seeking Alpha

Sep 03, 2024
pulisher
Sep 03, 2024

ImmunityBio, Inc. (NASDAQ:IBRX) Sees Significant Increase in Short Interest - MarketBeat

Sep 03, 2024
pulisher
Aug 30, 2024

ImmunityBio (NASDAQ:IBRX) Stock Price Up 3.7% - MarketBeat

Aug 30, 2024
pulisher
Aug 26, 2024

CG Oncology: Promising Data, But Looks Expensive (NASDAQ:CGON) - Seeking Alpha

Aug 26, 2024
pulisher
Aug 23, 2024

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - GlobeNewswire Inc.

Aug 23, 2024
pulisher
Aug 21, 2024

ImmunityBio (NASDAQ:IBRX) Trading 7.8% Higher - MarketBeat

Aug 21, 2024
pulisher
Aug 21, 2024

ImmunityBio (NASDAQ:IBRX) Trading Down 6% Following Analyst Downgrade - Defense World

Aug 21, 2024
pulisher
Aug 19, 2024

Piper Sandler Lowers ImmunityBio (NASDAQ:IBRX) Price Target to $4.75 - MarketBeat

Aug 19, 2024
pulisher
Aug 19, 2024

ImmunityBio (NASDAQ:IBRX) Stock Price Down 6% - MarketBeat

Aug 19, 2024
pulisher
Aug 19, 2024

ImmunityBio's Anktiva: Promising, But Organizational Complexity Keeps Me Cautious (IBRX) - Seeking Alpha

Aug 19, 2024
pulisher
Aug 17, 2024

ImmunityBio (NASDAQ:IBRX) Shares Gap Down to $3.88 - Defense World

Aug 17, 2024
pulisher
Aug 17, 2024

Aptose Biosciences (NASDAQ:APTO) vs. ImmunityBio (NASDAQ:IBRX) Critical Review - Defense World

Aug 17, 2024
pulisher
Aug 16, 2024

ImmunityBio (NASDAQ:IBRX) Shares Gap Down to $3.88 - MarketBeat

Aug 16, 2024
pulisher
Aug 16, 2024

California State Teachers Retirement System Reduces Holdings in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World

Aug 16, 2024
pulisher
Aug 16, 2024

Analyzing ImmunityBio (NASDAQ:IBRX) and Ginkgo Bioworks (NYSE:DNA) - Defense World

Aug 16, 2024
pulisher
Aug 14, 2024

ImmunityBio: Anktiva's Launch ProgressesBladder Cancer Drug May Be 'Real Deal' - Seeking Alpha

Aug 14, 2024
pulisher
Aug 14, 2024

ImmunityBio Second Quarter 2024 Earnings: Misses Expectations - Simply Wall St

Aug 14, 2024
pulisher
Aug 14, 2024

ImmunityBio (NASDAQ:IBRX) Shares Down 2.7% on Disappointing Earnings - Defense World

Aug 14, 2024
pulisher
Aug 13, 2024

Price T Rowe Associates Inc. MD Boosts Stock Holdings in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World

Aug 13, 2024
pulisher
Aug 13, 2024

Simplicity Wealth LLC Has $100,000 Position in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World

Aug 13, 2024
pulisher
Aug 13, 2024

ImmunityBio (NASDAQ:IBRX) Shares Down 2.7% Following Weak Earnings - MarketBeat

Aug 13, 2024
pulisher
Aug 13, 2024

ImmunityBio: Q2 Earnings Snapshot - San Antonio Express-News

Aug 13, 2024
pulisher
Aug 12, 2024

More Bladder Cancer Patients Can Access Innovative Therapy - Precision Vaccinations

Aug 12, 2024
pulisher
Aug 12, 2024

ImmunityBio: Q2 Earnings Snapshot - The Washington Post

Aug 12, 2024
pulisher
Aug 12, 2024

IBRX Stock Earnings: ImmunityBio Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace

Aug 12, 2024
pulisher
Aug 12, 2024

ImmunityBio: Q2 Earnings Snapshot - San Francisco Chronicle

Aug 12, 2024
pulisher
Aug 12, 2024

ImmunityBio (IBRX) Reports Q2 Loss, Lags Revenue Estimates - MSN

Aug 12, 2024
pulisher
Aug 12, 2024

ImmunityBio (IBRX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Aug 12, 2024
pulisher
Aug 12, 2024

ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval - StockTitan

Aug 12, 2024

Immunitybio Inc Stock (IBRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.53
price down icon 0.76%
$358.22
price up icon 1.10%
$58.29
price up icon 2.57%
$236.10
price down icon 1.37%
$120.52
price up icon 1.82%
$536.70
price up icon 1.79%
Cap:     |  Volume (24h):